ST吉药(300108) - 2021 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2021 was ¥165,254,931.72, representing a 17.16% increase compared to ¥141,053,032.34 in the same period last year[8]. - The net profit attributable to shareholders was a loss of ¥34,336,148.03, an improvement of 15.71% from a loss of ¥40,737,284.11 in the previous year[8]. - The basic and diluted earnings per share were both ¥-0.0516, showing a 15.76% improvement from ¥-0.0612 in the same period last year[8]. - The company reported a net profit loss of ¥15,122,055.85 for the current period, an improvement from a loss of ¥16,871,531.64 in the previous period, indicating a reduction in losses by approximately 10.4%[56]. - The total comprehensive loss for the current period was ¥15,122,055.85, compared to a loss of ¥16,871,531.64 in the previous period, showing a reduction in overall losses[57]. Cash Flow - The net cash flow from operating activities was ¥20,078,180.87, a significant increase of 126.18% compared to a negative cash flow of ¥76,683,121.92 in the same period last year[8]. - Operating cash flow for the current period was ¥20,078,180.87, a significant recovery compared to a negative cash flow of ¥76,683,121.92 in the previous period[61]. - The company reported cash inflows from operating activities totaling ¥147,564,850.90, down from ¥193,277,210.67 in the previous period[61]. - The cash balance at the end of the period was ¥25,883,304.23, a decrease of 45.63% compared to the beginning of the period, primarily due to tight liquidity[19]. - Cash and cash equivalents at the end of the period stood at ¥4,146,358.00, down from ¥31,182,430.40 at the end of the previous period[63]. Assets and Liabilities - The total assets at the end of the reporting period were ¥2,700,314,202.26, a decrease of 1.44% from ¥2,739,752,697.28 at the end of the previous year[8]. - Total current assets decreased to ¥892,862,992.53 from ¥908,536,195.57, reflecting a decline of about 1.7%[36]. - Total liabilities increased to CNY 1,313,478,034.92 from CNY 1,295,705,820.19, indicating a rise of 1.4%[46]. - The company's total liabilities decreased to ¥2,708,592,371.12 from ¥2,712,552,815.99, a reduction of approximately 0.1%[39]. - Current liabilities increased by 38.83% to ¥4,778,569.58, mainly due to an increase in advance sales payments[21]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 27,474[12]. - The top shareholder, Sun Jun, held 19.13% of the shares, amounting to 127,388,759 shares, with a significant portion pledged[12]. - The equity attributable to shareholders of the parent company was CNY 129,507,446.33, down from CNY 144,629,502.18[46]. Government Support and Investments - The company received government subsidies amounting to ¥580,686.83 during the reporting period[9]. - The company received tax refunds amounting to ¥691,911.11 during the current period[61]. - The company aims to expand its pharmaceutical business across China, focusing on biopharmaceuticals and OTC market sales, while enhancing group management[23]. - The company plans to accelerate investment project implementation to establish a well-known brand in the domestic market[24]. Operational Expenses - Sales expenses for the period were ¥22,404,827.77, an increase of 34.87% year-on-year, largely due to the resumption of sales activities after COVID-19 disruptions[22]. - Financial expenses for the period reached ¥30,427,505.34, up 78.09% year-on-year, primarily due to overdue borrowings and rising interest rates[22]. - The company incurred management expenses of ¥1,245,749.11, down from ¥7,256,104.91 in the previous period, reflecting a decrease of approximately 82.8%[56]. - Financial expenses increased to ¥13,876,107.43 from ¥9,617,271.73, with interest expenses accounting for ¥13,875,257.00, up from ¥9,429,259.98[56]. Inventory and Receivables - Accounts receivable increased to ¥379,399,390.51 from ¥356,718,305.95, showing a growth of about 6.3%[36]. - Inventory rose to ¥297,010,033.34 from ¥291,929,087.26, indicating an increase of approximately 1.7%[36]. - Other receivables at the end of the period amounted to ¥31,254,623.48, a decrease of 36.61% from the beginning of the period, attributed to enhanced management of receivables due to financial constraints[20]. Audit and Compliance - The company reported no violations of external guarantees during the reporting period[30]. - The company did not undergo an audit for the first quarter report[65].